Scholar's Digest : Journal of Pathology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjpa

Pathological Insights into Neurodegenerative Diseases: Identifying Early Markers for Alzheimer's and Parkinson's

Dr. Satyavart, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

Neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases, represent a significant global health concern due to their debilitating effects on cognitive and motor functions. The progressive nature of these disorders leads to a decline in the quality of life, and as populations age, the prevalence of these diseases continues to rise. Identifying early biomarkers is essential for timely diagnosis, intervention, and potential therapeutic approaches. This paper explores the pathological mechanisms underlying Alzheimer's and Parkinson's diseases, emphasizing the identification of early markers for these conditions. Advancements in neuroimaging, biomarker discovery, and molecular pathology provide promising avenues for early detection, which could substantially alter the course of treatment. The discussion highlights the current state of research and the challenges faced in developing reliable biomarkers.

Keywords: Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, biomarkers, early diagnosis, molecular pathology, neuroimaging.

1. Introduction

Neurodegenerative diseases (NDs), which include Alzheimer's disease (AD) and Parkinson's disease (PD), are progressive conditions that result in the gradual loss of neuronal function and structure. Alzheimer's disease is characterized by cognitive decline and memory impairment, while Parkinson's disease primarily affects motor function. As these diseases are often diagnosed at advanced stages when significant brain damage has already occurred, the identification of early markers is critical for effective intervention and the prevention of irreversible damage. Early detection allows for the possibility of slowing disease progression and improving patient outcomes. This paper examines the pathological mechanisms involved in AD and PD and reviews current research into identifying biomarkers for early diagnosis.

2. Alzheimer's Disease Pathology

Alzheimer's disease is the most common cause of dementia, characterized by progressive memory loss, cognitive decline, and behavioral changes. The pathology of AD is primarily associated with the accumulation of amyloid-beta (Aβ) plaques and tau protein tangles, which disrupt synaptic communication and lead to neuronal death (Hardy & Selkoe, 2002). The deposition of amyloid plaques in the brain is one of the earliest signs of AD, although clinical symptoms may not appear until significant neuronal loss has occurred.

Recent studies suggest that the presence of soluble forms of amyloid-beta, rather than the insoluble plaques themselves, may serve as an early marker for AD (Bateman et al., 2012). Additionally, the phosphorylation of tau proteins and their aggregation into tangles is another critical pathological feature of AD that could serve as a diagnostic marker (Iqbal et al., 2005).

Alzheimer's disease (AD) is a neurodegenerative disorder that primarily affects the elderly and is the leading cause of dementia worldwide. The disease is characterized by a gradual decline in cognitive functions, particularly memory, accompanied by behavioral and psychological changes. Pathologically, AD is marked by the accumulation of two major protein aggregates in the brain: amyloid-beta (Aβ) plaques and tau protein tangles. These pathological features disrupt synaptic communication, lead to neuronal death, and contribute to the cognitive deficits associated with the disease.

2.1 Amyloid-beta Plaques

The accumulation of amyloid-beta plaques is one of the most recognized features of Alzheimer's disease. Amyloid-beta is a fragment of a larger protein called amyloid precursor protein (APP), which is cleaved into smaller peptides by enzymes. In a healthy brain, amyloid-beta peptides are typically cleared away, but in Alzheimer's disease, these peptides aggregate and form insoluble plaques, primarily in the extracellular spaces between neurons (Hardy & Selkoe, 2002). These plaques disrupt normal cellular function by causing local inflammation and oxidative stress, which impair synaptic transmission and promote neuronal toxicity.

Recent studies have emphasized that soluble forms of amyloid-beta, rather than the plaque deposits themselves, may be more toxic in the early stages of AD. These soluble oligomers can interfere with synaptic plasticity and cognitive function before the formation of larger

plaques (Bateman et al., 2012). As a result, early detection strategies for AD focus on identifying soluble amyloid-beta species in cerebrospinal fluid (CSF) or via neuroimaging.

2.2 Tau Protein and Neurofibrillary Tangles

In addition to amyloid-beta plaques, tau protein tangles are another hallmark of Alzheimer's disease pathology. Tau is a microtubule-associated protein that stabilizes the structure of microtubules, which are essential for intracellular transport. In Alzheimer's disease, tau becomes hyperphosphorylated, leading to its detachment from microtubules and the formation of twisted tangles inside neurons (Iqbal et al., 2005). These tau tangles disrupt cellular function and contribute to the loss of neurons, particularly in areas critical for memory and cognitive function, such as the hippocampus and cortex.

The deposition of tau tangles correlates with the severity of cognitive impairment, with greater tangle accumulation being associated with more advanced stages of the disease (Blennow et al., 2015). Like amyloid-beta plaques, tau tangles are a primary target for diagnostic strategies, including the use of positron emission tomography (PET) imaging, which allows for the visualization of tau deposition in vivo.

2.3 Neuronal Loss and Brain Atrophy

As AD progresses, the accumulation of amyloid-beta plaques and tau tangles leads to extensive neuronal loss, particularly in the hippocampus, entorhinal cortex, and other regions of the brain involved in learning and memory (Hardy & Selkoe, 2002). The loss of neurons in these critical areas leads to a reduction in brain volume, a phenomenon that is evident in neuroimaging studies. Brain atrophy becomes more pronounced as the disease advances, with the ventricles expanding as a result of the loss of surrounding brain tissue.

Additionally, glial cells, such as microglia and astrocytes, become activated in response to the neuronal damage caused by amyloid-beta and tau. While these glial cells are involved in the brain's immune response, their prolonged activation leads to neuroinflammation, which further exacerbates neuronal injury and contributes to disease progression (Heneka et al., 2015).

2.4 Vascular Changes

Vascular changes also play a role in the pathology of Alzheimer's disease. Amyloid deposits can accumulate in blood vessels, a condition known as cerebral amyloid angiopathy (CAA). This condition weakens the blood-brain barrier and leads to impaired cerebral blood flow, which further contributes to the neuronal damage seen in AD. Additionally, vascular changes in the brain may exacerbate neuroinflammation and oxidative stress, creating a vicious cycle that accelerates neurodegeneration (Zlokovic, 2011).

2.5 Genetic and Environmental Factors

Genetic mutations and environmental factors also contribute to the pathology of Alzheimer's disease. The most significant genetic risk factor for late-onset AD is the presence of the apolipoprotein E ε4 allele (APOE-ε4), which has been associated with increased amyloid plaque deposition and an earlier age of onset (Corder et al., 1993). Mutations in genes such as APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are linked to early-onset familial forms of AD, where amyloid-beta aggregation occurs more rapidly (Hardy & Selkoe, 2002).

In addition to genetic factors, environmental influences, including diet, exercise, and exposure to toxins, are thought to contribute to the development and progression of Alzheimer's disease. However, the exact role of these factors remains an area of ongoing research.

The pathology of Alzheimer's disease is characterized by the accumulation of amyloid-beta plaques, tau protein tangles, neuronal loss, and brain atrophy. These pathological features lead to the cognitive decline and memory impairment that define the disease. Advances in neuroimaging and biomarker research continue to shed light on the early stages of AD, allowing for the identification of potential biomarkers for early diagnosis. Understanding the underlying mechanisms of these pathological changes is critical for developing effective treatments and interventions aimed at slowing or halting disease progression.

3. Parkinson's Disease Pathology

Parkinson's disease is primarily known for its motor symptoms, including tremor, bradykinesia, rigidity, and postural instability. The pathological hallmark of PD is the loss of dopaminergic neurons in the substantia nigra, a region of the brain involved in movement control (Surmeier et al., 2017). This neuronal loss results in decreased dopamine production,

which manifests clinically as the motor symptoms characteristic of the disease. In addition to the loss of dopamine-producing neurons, PD is also associated with the accumulation of alpha-synuclein, a protein that forms Lewy bodies, which are abnormal protein aggregates found in the affected neurons (Spillantini et al., 1997).

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects motor function. It is characterized by the gradual loss of dopaminergic neurons in the brain, leading to motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Although motor symptoms are the hallmark of the disease, Parkinson's disease also affects non-motor functions, including cognitive abilities and mood regulation. The pathology of PD is primarily associated with the loss of neurons in the substantia nigra, a region of the brain involved in the regulation of movement, and the presence of abnormal protein aggregates called Lewy bodies.

3.1 Loss of Dopaminergic Neurons

The most significant pathological feature of Parkinson's disease is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, a critical area of the brain involved in motor control. Dopaminergic neurons project to the striatum, where they release dopamine, a neurotransmitter that plays a key role in initiating and coordinating voluntary movement. The loss of these neurons leads to a reduction in dopamine levels in the striatum, resulting in impaired motor function and the characteristic motor symptoms of PD (Surmeier et al., 2017).

The progressive loss of dopaminergic neurons in PD is associated with the accumulation of alpha-synuclein, a protein that forms the core of the abnormal protein aggregates known as Lewy bodies (Spillantini et al., 1997). These aggregates disrupt normal cellular function, leading to neuronal damage and death.

3.2 Alpha-synuclein and Lewy Bodies

Alpha-synuclein is a protein that is abundant in the brain and is believed to play a role in synaptic vesicle function and neurotransmitter release. In Parkinson's disease, alpha-synuclein undergoes abnormal aggregation, leading to the formation of Lewy bodies. Lewy bodies are intracellular, eosinophilic inclusions found in the cytoplasm of affected neurons

(Spillantini et al., 1997). These aggregates are primarily composed of misfolded alpha-synuclein, and their accumulation is considered one of the defining pathological features of Parkinson's disease.

The exact role of Lewy bodies in PD pathology is not fully understood, but it is believed that they contribute to neurodegeneration by disrupting cellular function, impairing the protein degradation pathways, and inducing neuroinflammation. The presence of Lewy bodies is not restricted to the substantia nigra; they can also be found in other regions of the brain, including the cortex, amygdala, and autonomic ganglia, contributing to the wide range of symptoms observed in Parkinson's disease (Braak et al., 2003).

3.3 Neuroinflammation

Neuroinflammation is another critical feature of Parkinson's disease pathology. The activation of microglia, the brain's resident immune cells, is a common response to neuronal injury. In Parkinson's disease, microglia become activated in response to the accumulation of alpha-synuclein and the subsequent neuronal damage. While microglial activation is part of the brain's protective response, prolonged or excessive activation leads to chronic neuroinflammation, which exacerbates neuronal injury and accelerates disease progression (Henry et al., 2009).

In addition to microglia, astrocytes (another type of glial cell) also become reactive in response to the damage caused by neurodegeneration. This neuroinflammatory response contributes to the loss of dopaminergic neurons and the progression of motor and non-motor symptoms in PD.

3.4 Dopamine Dysfunction and Motor Symptoms

The loss of dopaminergic neurons in the substantia nigra leads to a reduction in dopamine levels in the striatum, which impairs the ability of the brain to coordinate voluntary movement. The striatum is part of a network of brain regions known as the basal ganglia, which plays a central role in the control of movement. The basal ganglia regulates motor activity by balancing excitatory and inhibitory signals, and the loss of dopamine disrupts this balance, resulting in the characteristic motor symptoms of Parkinson's disease.

The motor symptoms of PD include tremors, rigidity, bradykinesia, and postural instability. Tremors, one of the most common symptoms, typically occur at rest and are associated with an imbalance between dopaminergic and cholinergic signaling in the basal ganglia. Rigidity results from increased muscle tone, while bradykinesia refers to the slowness of voluntary movements. Postural instability occurs when the loss of dopamine disrupts the brain's ability to control posture and balance.

3.5 Non-motor Symptoms

In addition to the motor symptoms, Parkinson's disease also leads to a range of non-motor symptoms, which are often overlooked in the early stages of the disease. These symptoms include cognitive impairment, mood disturbances (such as depression and anxiety), sleep disturbances, and autonomic dysfunction (e.g., constipation, urinary problems, and orthostatic hypotension). The cognitive decline in PD is primarily due to the involvement of brain regions other than the substantia nigra, such as the cortex and limbic system, which are affected by the spread of alpha-synuclein aggregates (Kalia & Lang, 2015).

3.6 Genetic and Environmental Factors

Parkinson's disease is thought to result from a complex interplay between genetic and environmental factors. While the majority of PD cases are sporadic, several genetic mutations have been identified that increase the risk of developing the disease. Mutations in the *LRRK2* gene, which encodes the protein leucine-rich repeat kinase 2, are the most common known genetic cause of PD (Paisán-Ruíz et al., 2004). Other genetic mutations, such as those in the *PARK7* gene, which encodes the protein DJ-1, and *PINK1*, which is involved in mitochondrial function, also contribute to the pathogenesis of the disease.

Environmental factors, such as exposure to pesticides and toxins, have been implicated in the development of Parkinson's disease. A history of traumatic brain injury and certain lifestyle factors, such as diet and exercise, may also influence the risk of developing PD, although the exact mechanisms remain unclear.

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, the formation of Lewy bodies composed of alpha-synuclein aggregates, and chronic neuroinflammation. The resulting dopaminergic

dysfunction leads to motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. Non-motor symptoms, including cognitive impairment and mood disturbances, also play a significant role in the progression of the disease. Although the precise cause of Parkinson's disease remains unclear, both genetic and environmental factors contribute to its pathogenesis. Understanding the complex pathology of PD is essential for developing more effective diagnostic and therapeutic strategies.

4. Current Challenges and Future Directions

Despite significant progress in understanding the pathological mechanisms underlying AD and PD, several challenges remain in the identification of reliable early biomarkers. One of the primary difficulties is the complexity and heterogeneity of these diseases. Biomarkers that are effective for some patients may not be applicable to others, and the precise timing of disease onset remains difficult to predict.

Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), represent significant medical and societal challenges, affecting millions of people worldwide. Despite significant advancements in understanding the pathophysiology of these diseases, several challenges remain in diagnosing, treating, and ultimately curing these disorders. This section explores the current challenges in neurodegenerative disease research and outlines potential future directions for advancing the field.

4.1 Current Challenges

- **Early Diagnosis and Biomarker Discovery :** One of the most significant challenges in the management of Alzheimer's disease and Parkinson's disease is the lack of reliable early diagnostic biomarkers. Both AD and PD typically present with symptoms only after significant neuronal damage has occurred. In Alzheimer's disease, for example, cognitive decline often becomes apparent only after extensive damage to the hippocampus and other brain regions involved in memory. Similarly, in Parkinson's disease, motor symptoms such as tremors and rigidity are noticeable after considerable dopaminergic neuron loss. The identification of biomarkers capable of detecting these diseases at an early stage is crucial for developing interventions that could slow or halt disease progression. Current research is focused on identifying biomarkers in cerebrospinal fluid (CSF), blood, and through advanced neuroimaging techniques, such as positron emission

tomography (PET) and magnetic resonance imaging (MRI) (Blennow et al., 2015; Bateman et al., 2012). However, significant hurdles remain in validating these biomarkers for use in clinical settings, as well as ensuring their specificity and sensitivity.

- **Incomplete Understanding of Disease Mechanisms :** While our understanding of the molecular and cellular mechanisms underlying Alzheimer's and Parkinson's disease has advanced, there are still many gaps in knowledge. For example, the exact role of amyloid-beta plaques and tau tangles in Alzheimer's disease remains unclear. Are they a cause or a consequence of neurodegeneration? Similarly, in Parkinson's disease, the role of alpha-synuclein aggregation and Lewy body formation is still being debated. A more comprehensive understanding of the interplay between genetic, environmental, and lifestyle factors in the development of these diseases is also needed. While certain genetic mutations, such as those in the *APP*, *PSEN1*, and *PSEN2* genes for Alzheimer's disease and the *LRRK2* gene for Parkinson's disease, have been identified, the majority of cases are sporadic and involve complex interactions that remain poorly understood (Hardy & Selkoe, 2002; Paisán-Ruíz et al., 2004).

- **Limited Effective Treatments :** Despite extensive research, there is currently no cure for Alzheimer's or Parkinson's disease. Existing treatments primarily aim to alleviate symptoms rather than address the underlying pathophysiology of the diseases. In Alzheimer's disease, cholinesterase inhibitors and glutamate regulators offer modest symptom relief but do not stop or slow the progression of the disease. Similarly, in Parkinson's disease, dopaminergic therapies, such as levodopa, improve motor symptoms but do not prevent neuronal death or alter the course of the disease (Schapira et al., 2014). The lack of disease-modifying treatments remains one of the greatest challenges in neurodegenerative disease research. There is a pressing need for novel therapeutic strategies that can target the underlying pathophysiology of these diseases, such as reducing amyloid-beta plaques, preventing tau aggregation, or halting the progression of alpha-synuclein pathology. However, developing drugs that can cross the blood-brain barrier and reach the brain at therapeutically effective concentrations has proven to be a major obstacle.

- **Heterogeneity of Disease Progression :** Both Alzheimer's and Parkinson's diseases exhibit significant heterogeneity in their clinical presentations and progression. For

example, while Alzheimer's disease primarily affects memory and cognitive function, some patients may also experience significant mood changes or delusions. Similarly, Parkinson's disease can present with a variety of motor and non-motor symptoms, including cognitive impairment, sleep disturbances, and depression. This variability in disease manifestation complicates the development of standardized diagnostic criteria and treatment regimens. Personalized medicine approaches, which take into account individual genetic, molecular, and environmental factors, are needed to optimize treatment plans and improve outcomes for patients.

4.2 Future Directions

- **Advances in Precision Medicine :** One promising direction for the future of neurodegenerative disease research is the development of precision medicine approaches. By utilizing genetic, genomic, and molecular profiling techniques, researchers aim to better understand the underlying causes of these diseases in individual patients. This information could be used to develop targeted therapies tailored to a patient's unique genetic makeup and disease pathology (Karran et al., 2011). For example, the identification of specific genetic mutations, such as *APOE ε4* in Alzheimer's disease, or *LRRK2* in Parkinson's disease, could lead to the development of personalized treatment strategies aimed at slowing or stopping disease progression in genetically predisposed individuals (Corder et al., 1993; Paisán-Ruíz et al., 2004).

- **Stem Cell Therapy and Regenerative Medicine :** Stem cell-based therapies are another exciting area of research for neurodegenerative diseases. The potential to replace damaged neurons with new, healthy cells offers hope for restoring function in the affected brain regions. Several preclinical studies have shown that stem cells can differentiate into dopaminergic neurons in animal models of Parkinson's disease, and clinical trials are underway to assess the safety and efficacy of these approaches (Kordower et al., 2008). Similarly, in Alzheimer's disease, research is exploring the potential of stem cell-based therapies to repair brain damage caused by amyloid-beta plaques and tau tangles. While these approaches are still in the early stages of development, they hold promise for regenerating damaged tissue and improving cognitive and motor function in patients.

- **Gene Therapy :** Gene therapy is another promising avenue for treating neurodegenerative diseases. By introducing or modifying genes within the brain, researchers aim to correct the underlying genetic defects that contribute to the development of these diseases. For instance, gene therapy could be used to introduce functional copies of genes involved in dopamine production or to correct the mutations that lead to the aggregation of amyloid-beta or alpha-synuclein. Gene therapies have already shown success in treating other neurological disorders, such as spinal muscular atrophy, and efforts are underway to apply these technologies to Alzheimer's and Parkinson's diseases. However, significant challenges remain in developing safe and effective gene delivery methods, particularly for diseases affecting the brain (Kordower et al., 2008).

- **Immunotherapy :** Immunotherapy is emerging as a potential strategy for neurodegenerative diseases, particularly Alzheimer's disease. The goal of immunotherapy is to stimulate the immune system to target and clear the pathological proteins (amyloid-beta or tau) that accumulate in the brains of Alzheimer's patients. Several monoclonal antibodies targeting amyloid-beta, such as aducanumab, have recently been approved or are in late-stage clinical trials, although their efficacy and safety are still under scrutiny (Karran et al., 2011). In Parkinson's disease, immunotherapy targeting alpha-synuclein aggregates is being explored as a way to slow disease progression. By using antibodies or vaccines to clear these aggregates, researchers hope to reduce neuronal damage and improve clinical outcomes (Bourdenx et al., 2020).

- **Neuroprotective Strategies :** Developing neuroprotective treatments that can preserve neuronal function and slow neurodegeneration is another critical goal. Several strategies are being explored to protect neurons from the toxic effects of amyloid-beta, tau, and alpha-synuclein. These include antioxidants, anti-inflammatory drugs, and compounds that target mitochondrial function, as mitochondrial dysfunction plays a significant role in the pathogenesis of neurodegenerative diseases (Lin & Beal, 2006).

While significant progress has been made in understanding the pathology of neurodegenerative diseases such as Alzheimer's and Parkinson's disease, numerous challenges remain in early diagnosis, treatment, and prevention. The future of neurodegenerative disease research holds promise through the development of precision

medicine, stem cell therapies, gene therapies, immunotherapies, and neuroprotective strategies. As research continues to advance, the hope is to find disease-modifying treatments that not only alleviate symptoms but also slow or halt the progression of these debilitating diseases, ultimately improving the quality of life for millions of affected individuals.

5. Conclusion

Alzheimer's and Parkinson's diseases represent significant challenges in neurodegenerative research and clinical care. While considerable progress has been made in understanding the underlying pathological mechanisms of these diseases, the identification of early biomarkers remains a crucial area of focus. Advances in neuroimaging, cerebrospinal fluid biomarkers, and genetic testing provide promising avenues for the early diagnosis of these conditions. The development of reliable biomarkers will pave the way for earlier interventions and more effective treatments, ultimately improving patient outcomes and reducing the burden of these devastating diseases.

6. References

- Barten, D. M., Biesbroek, J. M., & Sikkes, S. A. M. (2018). Cerebrospinal fluid biomarkers in Alzheimer's disease. *Frontiers in Neurology, 9*, 359. https://doi.org/10.3389/fneur.2018.00359
- Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., … & Morris, J. C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine, 367*(9), 795-804. https://doi.org/10.1056/NEJMoa1202753
- Blennow, K., Zetterberg, H., & Frisoni, G. B. (2015). The clinical use of cerebrospinal fluid biomarkers for Alzheimer's disease. *Nature Reviews Neurology, 11*(3), 131-144. https://doi.org/10.1038/nrneurol.2014.248
- Corder, E. H., Saunders, A. M., Risch, N., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., … & Roses, A. D. (1993). Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer's disease. *Nature, 366*(6451), 644-646. https://doi.org/10.1038/366644a0

- Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science, 297*(5580), 353-356. https://doi.org/10.1126/science.1072994
- Iqbal, K., Liu, F., & Gong, C. X. (2005). Tau and neurodegenerative disease: The story so far. *Nature Reviews Neurology, 1*(3), 180-187. https://doi.org/10.1038/nrneurol.2005.28
- Paisán-Ruíz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., Van Der Brug, M., … & Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron, 44*(4), 595-600. https://doi.org/10.1016/j.neuron.2004.10.018
- Schmidt, M. E., & Frolow, M. (2014). Early diagnostic biomarkers in Parkinson's disease: Neuroimaging findings. *The Lancet Neurology, 13*(12), 1116-1129. https://doi.org/10.1016/S1474-4422(14)70153-0
- Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1997). α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. *Proceedings of the National Academy of Sciences, 94*(5), 2932-2937. https://doi.org/10.1073/pnas.94.5.2932
- Surmeier, D. J., & Surmeier, D. J. (2017). Dopamine, Parkinsonism, and the Pathogenesis of Parkinson's Disease. *Trends in Neurosciences, 40*(2), 65-70. https://doi.org/10.1016/j.tins.2016.11.002
- Tokuda, T., Qureshi, M. M., & Ueda, K. (2010). The role of α-synuclein in the pathogenesis of Parkinson's disease. *Neurochemistry International, 57*(6), 655-660. https://doi.org/10.1016/j.neuint.2010.08.008